Scancell Share Discussion Threads

[bermudashorts] 10/7/2024 18:28

inanaco - yes that's my understanding

[moljen] 10/7/2024 18:23

Thought this was a litter free thread?

[inanaco] 10/7/2024 18:18

unless

scib1 plus pd-1 43
scib1 doublet 43
iscib1 43

= 129

[inanaco] 10/7/2024 18:16

well 43 scib1 plus 43 iscib1 = 86

trial indicates 130 ?

[bermudashorts] 10/7/2024 17:54

inanaco,

Thought they were going for 43 iSCIB1+ patients?

[inanaco] 10/7/2024 17:52

SC102 ... efficacy is the game in town ...

Prove it

there are no negatives to the trial that need investigation

its not a marginal improvement !

[sci102] 10/7/2024 17:49

"Accelerated approval after the results of the phase 3 trial"

🤣🤣🤣🤣9315;🤣ԍ15;🤣🤣;🤣
You can't make this stuff up.

Note that aceelerated approval is given after phase 2, given that phase 3 has already started., not after the phase 3 results. After the phase 3 results, you either get marketing authorisation or you don't anyway,, nothing accelerated about that 🤣🤣🤣🤣

[inanaco] 10/7/2024 17:48

its possible that the phase 2/3 adaptable could change to a phase 3 only

[inanaco] 10/7/2024 17:45

Bermuda

They may have already changed ! why go for so many patients with iScib1 now ? (130 total)

that's 87

behind closed doors

[pharmaboy3] 10/7/2024 16:33

Try again!HTTps://newspaper.mailplus.co.uk/data/4613/reader/reader.html?social#!preferred/0/package/4613/pub/15588/page/58/alb/800439

[bermudashorts] 10/7/2024 16:30

Marcus, worth noting too the comment about accelerated approval in view of previous discussions on the matter! Of course there's a long way to go and it'll be in the hands of the regulators but clearly there's an intention to explore the possibilty of accelerated approval based on progression free survival data:-

'Scancell hopes that PFS data from the trial's phase 3 portion will be enough for an accelerated nod, with overall survival results from the same study being used for full approval.'

[pharmaboy3] 10/7/2024 16:30

Nice article in Mail re next blockbuster HTTps://newspaper.mailplus.co.uk/data/4613/reader/reader.html?#!preferred/0/package/4613/pub/15588/page/58/content/800439

[markingtime] 10/7/2024 16:16

.....this would also be an ideal time for a large pharma to take the whole company out, lock stock & barrel. Because they have the capacity to run all the trials without raising finance.

[sci102] 10/7/2024 16:13

It is nearly time to update my report.
Will do next week probably when I'll have more time.

[sci102] 10/7/2024 15:56

This is the first honest article I have read about scancell.



LD's chronic lying might still cause damage. They should have been less pompous about iSCIB+ and focused all communications on SCIB1, as I explained in my report in the first post of this thread. Now, all of a sudden clinical trials ate unpredictable.
By the way,

Sci102 - 30 Jan 2024 - 14:41:33 - 80 of 440
Why they keep mentioning 70% as the target for the trial when it's what this trial is *powered* to show. 27/43 is 63%

Not to mention that SCIB1 sometimes targets 30% of patients and some other times 40% and according to this article they could still use it for everyone (the only "dark spot" in the article)

Of course there is still no mention of accelerated approval (and rightly so) that marcus still wetdreams about.

None of that was necessary and hopefully we can expect a more reliable communication from now on.

PS of course Bermuda made no comment on the article, because he is in fact clueless :)

PS2 and according to chillintime LD is great because even though she does not communicate often (because she is so serious LMAO), she is always very to the point 🤣🤣🤣🤣9315;🤣ԍ15;

PS3 The CFO was right, there is 15.5 years of patent life left for iSCIB1+, not 18 like the CEO said recently. Chronic liar.

PS4 I did not notice the first tume that LD said they might get an accelerated nod af6er the phase 3 results🤣9315;🤣ԍ15; She needs to drop the CEO position YESTERDAY

[bermudashorts] 10/7/2024 15:33

Marcus,

Thanks for your 9614 - good spot. A balanced article from Madeleine Armstrong which gives some clarity on Scancell's current thinking regarding the phase 2/3.

[marcusl2] 10/7/2024 14:52

By 12th Jan hopefully a few quid from this and one further deal will help the finances a little.

International biotechnology company will evaluate its anti-glycan monoclonal antibody developed using Scancell's GlyMab platform.

The unnamed company will pay $1 million within 30 days for seven months of exclusive evaluation rights.

[marcusl2] 10/7/2024 14:41

This is why Scancell wants data on both before deciding which to take into an adaptive phase 2/3 trial, which could start in the first half of 2025. The design still needs to be nailed down with regulators, but Durrant says it will likely involve around 100 phase 2 patients, who would then roll over into a 300-patient phase 3 part. Half would receive SCIB1/iSCIB1+ plus Opdivo and Yervoy, and half the doublet alone.

However, Durrant is convinced that Opdivo/Yervoy is the right choice, saying that this produces better response rates, if patients can tolerate the toxicity.

Scope also gave physicians the choice of administering SCIB1/iSCIB1+ alongside Keytruda, but has only managed to recruit four patients to this combo arm. “That tells you how much the clinicians prefer [Opdivo/Yervoy].”

Scancell hopes that PFS data from the trial's phase 3 portion will be enough for an accelerated nod, with overall survival results from the same study being used for full approval.

But even getting this trial started will depend on fresh funding. Durrant admits that these types of immunotherapies have a poor history, so "you probably need to do a randomised phase 2 to get a partner".

[inanaco] 10/7/2024 13:56

Look at the number of sites delivering SCIB1 or Iscib1 and being set up ....

They are setting up for the registrational trials

Board expanded to accommodate with two major funding Players now at the table

talk about Ducks in a Row ....

[inanaco] 10/7/2024 13:48

Chilltime

Moditope is a peptide vaccine

SCIB1 is not its a MAB and a Plasmid both of which have an effect as the plasmid makes the Mab but also gives a first signal to the Dendritic Cell

But whats interesting is

The results coming soon transform the potential of the immunobody platform

look at MRNA

the general market pounced on any developer !!! throwing Billions at it

There is only ONE Immunobody

[inanaco] 10/7/2024 13:39

Purfect .....

Redmile have a seat so that's all the Big Guns at the table ready to take this forward with Loans Extended .....

why would you do that with no good news coming .... ?

Happy Birthday TF ... 77

my latest hobby

Catching Blunt Knives

[chilltime] 10/7/2024 13:16

Repeating myself

I said long ago that Scancell is poor on updating the market, that continues to be the case.

Qualifying poor.

Poor in terms of comparisons to a host of AIM shares that flood the market with news after news, same topic, which attracts the masses of news hungry investors. Most of such news is either hype, hope or just plain lies.

In Scancell you have scientists running the show, doing what they do. Years of experience of hope and promising looking candidates, the vast majority of which fail.

Lindy is all about real evidence not hope or hype. She said when there is something to shout about she will shout.

The last interview was the start of the shout but in a calm unassuming non AIM way.

A few it seems now CR re Melanoma, Lindy now convinced she has cracked it as she says.

The real shouting comes when you have the data to present, then the brakes start to come off, the media catch on and so on.

Step one towards the approaching fanfare appears to be the appointment today, perhaps the change of nomad too, lining up the ducks for the inevitable material interest from the majors which will already be in play (some are already involved after all)

It feels like a painful wait and the share price lags where it should be. In the hands of a pump CEO it would be multiples of where it is now.

On its current path of results it will be multiples of now. The difference will be, it won’t be there on hope, it will be there based on the science.

The hope/hype will then come on top of that for the other aspects of Scancell, along with anticipation of a buy out.

In revenue terms it’s not just about what Scancell have but what the likes of Scib can do for big name revenue earners which are nearing the end of their patent.

They with Scib making it to market can effectively extend their own treatments by many years, exclusivity or owning scib. The retained revenue from those would easily make even a big number for Scancell a no brainer financially.

Some very interesting few months ahead.

Those looking on or in and out in these doldrums may end up kicking themselves.

Peptide vaccines like this are new, drowned out by hype elsewhere. It’s looking like the real deal potentially knocking the standard of care out of the park.

Cheaper, safe, off the shelf, no complicated storage, a step change.

[rogerbridge] 10/7/2024 13:14

Especiallly taking into account that major shareholders paid more.